Comorbidity defines asthmatic patients' risk of COVID-19 hospitalization: A global perspective.

"Disclosure of potential conflict of interest: C. Skevaki reports consultancy and research funding from Hycor Biomedical, Bencard Allergie and Thermo Fisher Scientific, as well as research funding from Mead Johnson Nutrition. D. Fomina reports receiving honoraria from Novartis, Shire, Takeda, and Behring CSL. G. Rohde reports personal fees from AstraZeneca, Berlin Chemie, BMS, Boehringer Ingelheim, Chiesi, Essex Pharma, Grifols, GSK, Insmed, MSD, Roche, Solvay, Takeda, Novartis, Pfizer and Vertex for consultancy during advisory board meetings and personal fees from AstraZeneca, Berlin Chemie, BMS, Boehringer Ingelheim, Chiesi, Essex Pharma, Grifols, GSK, Insmed, MSD, Roche, Solvay, Takeda, Novartis, Pfizer and Vertex for lectures, including service on speakers bureaus. R. S. Chinthrajah reports receiving grant support from the Consortium for Food Allergy Research, National Institute of Allergy and Infectious Diseases (NIAID), Food Allergy Research and Education (FARE), Aimmune, DBV Technologies, Astellas, Novartis, Regeneron, and AstraZeneca and serving as an advisory board member for Alladapt Immunotherapeutics, Novartis, Sanofi, Allergenis, Intrommune Therapeutics, and Genentech. K. C. Nadeau reports receiving research funding from the NIAID; National Heart, Lung, and Blood Institute; National Institute of Environmental Health Sciences; and FARE. In addition, K. C. Nadeau reports being the director of the World Allergy Organization; serving as an adviser to Cour Pharma; being a cofounder of Before Brands, Alladapt, Latitude, and Ig-Genix; performing consultancy for Excellergy, Red Tree Ventures, and Phylaxis; being a member of the National Scientific Committee, Immune Tolerance Network, and National Institutes of Health clinical research centers; and holding the patents "Mixed Allergen Composition and Methods for Using the Same," "Granulocyte-Based Methods for Detecting and Monitoring Immune System Disorders," "Methods and Assays for Detecting and Quantifying Pure Subpopulations of White Blood Cells in Immune System Disorders," and "Methods of Isolating Allergen-Specific Antibodies from humans and Uses Thereof." The rest of the authors declare that they have no relevant conflicts of interest."

"Supported by the Universities Giessen and Marburg Lung Center, German Center for Lung Research, University Hospital Giessen and Marburg research funding according to Article 2, Section 3 of the Cooperation Agreement, and the Deutsche Forschungsgemeinschaft (German Research Foundation)-SFB 1021 (project identifier 197785619), KFO 309 (project identifier 284237345), and SK 317/1-1 (project identifier 428518790), and the Foundation for Pathobiochemistry and Molecular Diagnostics (to C.S.). Disclosure of potential conflict of interest: C. Skevaki reports consultancy and research funding from Hycor Biomedical, Bencard Allergie and Thermo Fisher Scientific, as well as research funding from Mead Johnson Nutrition. D. Fomina reports receiving honoraria from Novartis, Shire, Takeda, and Behring CSL. G. Rohde reports personal fees from AstraZeneca, Berlin Chemie, BMS, Boehringer Ingelheim, Chiesi, Essex Pharma, Grifols, GSK, Insmed, MSD, Roche, Solvay, Takeda, Novartis, Pfizer and Vertex for consultancy during advisory board meetings and personal fees from AstraZeneca, Berlin Chemie, BMS, Boehringer Ingelheim, Chiesi, Essex Pharma, Grifols, GSK, Insmed, MSD, Roche, Solvay, Takeda, Novartis, Pfizer and Vertex for lectures, including service on speakers bureaus. R. S. Chinthrajah reports receiving grant support from the Consortium for Food Allergy Research, National Institute of Allergy and Infectious Diseases (NIAID), Food Allergy Research and Education (FARE), Aimmune, DBV Technologies, Astellas, Novartis, Regeneron, and AstraZeneca and serving as an advisory board member for Alladapt Immunotherapeutics, Novartis, Sanofi, Allergenis, Intrommune Therapeutics, and Genentech. K. C. Nadeau reports receiving research funding from the NIAID; National Heart, Lung, and Blood Institute; National Institute of Environmental Health Sciences; and FARE. In addition, K. C. Nadeau reports being the director of the World Allergy Organization; serving as an adviser to Cour Pharma; being a cofounder of Before Brands, Alladapt, Latitude, and Ig-Genix; performing consultancy for Excellergy, Red Tree Ventures, and Phylaxis; being a member of the National Scientific Committee, Immune Tolerance Network, and National Institutes of Health clinical research centers; and holding the patents "Mixed Allergen Composition and Methods for Using the Same," "Granulocyte-Based Methods for Detecting and Monitoring Immune System Disorders," "Methods and Assays for Detecting and Quantifying Pure Subpopulations of White Blood Cells in Immune System Disorders," and "Methods of Isolating Allergen-Specific Antibodies from humans and Uses Thereof." The rest of the authors declare that they have no relevant conflicts of interest."